In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines

Investigational New Drugs

Volumn 30, Issue 2, 2012, Pages 480-489

  Schmidt Hieber, Martin ^a,c   Dabrowski, Robert ^a   Weimann, Andreas ^a   Aicher, Babette ^b   Lohneis, Philipp ^a   Busse, Antonia ^a   Thiel, Eckhard ^a   Blau, Igor W ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Æterna Zentaris GmbH   (Germany)

^c Centro de Investigacion del Cancer   (Spain)

Author keywords

Bortezomib; Caspases; Cytotoxic agents; D 21266 (Perifosine); Flow cytometry; In vitro; Lenalidomide

Indexed keywords

BORTEZOMIB; CASPASE 3; KI 67 ANTIGEN; LENALIDOMIDE; PERIFOSINE; TRYPAN BLUE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; CASP3 PROTEIN, HUMAN; DRUG DERIVATIVE; PHOSPHORYLCHOLINE; PYRAZINE DERIVATIVE; THALIDOMIDE;

APOPTOSIS; ARTICLE; ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; FLOW CYTOMETRY; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN TISSUE; IMMATURE MYELOID INFORMATION TECHNIQUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MULTIPLE MYELOMA; PRIORITY JOURNAL; CELL PROLIFERATION; CELL STRAIN HL 60; CELL STRAIN K 562; CELL SURVIVAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; IC 50; LYMPHOMA; METABOLISM; MYELOID LEUKEMIA; PATHOLOGY; TIME; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BORONIC ACIDS; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FLOW CYTOMETRY; HL-60 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITORY CONCENTRATION 50; K562 CELLS; KI-67 ANTIGEN; LEUKEMIA, MYELOID; LYMPHOMA; MULTIPLE MYELOMA; PHOSPHORYLCHOLINE; PYRAZINES; THALIDOMIDE; TIME FACTORS;

EID: 84862250288     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9576-2     Document Type: Article

References (30)

1. Mitsiades CS, Hideshima T, Chauhan D et al (2009) Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. Semin Hematol 46:166-175
2. Unger C, Berdel W, Hanauske AR et al (2010) First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumours. Eur J Cancer 46:920-925
3. Jiménez-López JM, Ríos-Marco P, Marco C et al (2010) Alterations in the homeostasis of phospholipids and cholesterol by antitumor alkylphospholipids. Lipids Health Dis 9:33
4. Gajate C, Mollinedo F (2007) Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood 109:711-719
5. Lentzsch S, Chatterjee M, Gries M et al (2004) PI3-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells. Leukemia 18:1883-1890
6. Hideshima T, Catley L, Raje N et al (2007) Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br J Haematol 138:783-791
7. Zerp SF, Vink SR, Ruiter GA et al (2008) Alkylphospholipids inhibit capillary-like endothelial tube formation in vitro: antiangiogenic properties of a new class of antitumor agents. Anticancer Drugs 19:65-75
8. Fu L, Kim YA, Wang X et al (2009) Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy. Cancer Res 69:8967-8976
9. Chanan-Khan AA, Giralt S (2010) Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol 28:2612-2624
10. Ogata A, Chauhan D, Urashima M et al (1997) Blockade of mitogen-activated protein kinase cascade signaling in interleukin-6 independent multiple myeloma cells. Clin Cancer Res 3:1017-1022
11. Hideshima T, Catley L, Yasui H et al (2006) Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 107:4053-4062
12. Hideshima T, Richardson P, Chauhan D et al (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071-3076
13. Schmidt-Hieber M, Busse A, Reufi B et al (2009) Bendamustine, but not fludarabine, exhibits a low stem cell toxicity in vitro. J Cancer Res Clin Oncol 135:227-234
14. Kondo T (1967) Hemolysis by surface-active agents. Hyomen 5:630-635
15. Eugene LG (1967) Lipids of human leukocytes: relation to cell type. J Lipid Res 8:321-327
16. Eugene LG (1972) Lipid patterns of leukocytes in health and disease. Semin Hematol 9:241-50
17. Reed LJ, Muench H (1938) A simple method of estimating fifty per cent endpoints. Am J Hyg 27:493-497
18. Richardson P, Wolf J, Jakubowiak A et al (2008) Phase I/II results of a multicenter trial of perifosine (KRX-0401) + bortezomib in patients with relapsed or relapsed/refractory multiple myeloma who were previously relapsed from or refractory to bortezomib. Blood 112(Suppl 11):870
19. Chen N, Lau H, Kong L et al (2007) Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol 47:1466-1475
20. Görgün G, Calabrese E, Soydan E et al (2010) Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood Jul 22 [Epub ahead of print]
21. Chauhan D, Singh AV, Ciccarelli B et al (2010) Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. Blood 115:834-845
22. Verhelle D, Corral LG, Wong K et al (2007) Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res 67:746-755
23. Servida F, Soligo D, Delia D et al (2005) Sensitivity of human multiple myelomas and myeloid leukemias to the proteasome inhibitor I. Leukemia 19:2324-2331
24. Reece DE, Sullivan D, Lonial S et al (2010) Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma. Cancer Chemother Pharmacol Mar 20 [Epub ahead of print].
25. Crul M, Rosing H, de Klerk GJ et al (2002) Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur J Cancer 38:1615-1621
26. Chiarini F, Del Sole M, Mongiorgi S et al (2008) The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism. Leukemia 22:1106-1116
27. Hennessy BT, Lu Y, Poradosu E et al (2007) Pharmacodynamic markers of perifosine efficacy. Clin Cancer Res 13:7421-7431
28. Vink SR, Schellens JH, van Blitterswijk WJ et al (2005) Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid. Invest New Drugs 23:279-286
29. Linssen J, Aderhold S, Nierhaus A et al (2008) Automation and validation of a rapid method to assess neutrophil and monocyte activation by routine fluorescence flow cytometry in vitro. Cytometry B Clin Cytom 74:295-309
30. Carrasco MP, Jiménez-López JM, Ríos-Marco P et al (2010) Disruption of cellular cholesterol transport and homeostasis as a novel mechanism of action of membrane-targeted alkylphospholipid analogues. Br J Pharmacol 160:355-366